HC9 Ventures

Our portfolio includes companies at all stages of development, from early-stage companies testing transformative technologies to commercial-stage companies seeking additional growth. With a focus on areas with significant unmet need, Vertex seeks to build great companies that improve the health and quality of human life. We take an active role in our portfolio companies and work with exceptional entrepreneurs, industry partners and fellow venture investors to create value. Our global investment professionals bring deep scientific, medical and business knowledge to every investment we make. In an increasingly globalized economy, Vertex Ventures HC offers global expertise to companies around the world. With offices in Silicon Valley and Singapore, our investment team scouts and invests in promising companies in the U.S., Asia and beyond. Our team, along with our network of scientific advisors and venture partners, has deep local networks and capabilities in both emerging and established markets. Our agile structure means we can act quickly on investment opportunities.

HealthCap is a European venture capital firm investing exclusively and globally in life sciences. The investment strategy focuses on diseases with high unmet medical needs and breakthrough therapies that have the potential to be transformative and change medical practice, and the lives of patients suffering these conditions. Having raised more than EUR 1.2 billion since 1996, HealthCap has backed and built more than 125 companies, taken more than 45 companies public and done numerous trade sales. Over the years, HealthCap companies have developed more than 25 pharmaceutical products to market approval, many of which are breakthrough therapies helping patients with life-threatening diseases. In addition, HealthCap companies have brought more than 50 innovative medical device products to market. These products have generated significant value to many stakeholders, including patients, physicians and society, and as a result also to HealthCap investors.

Headquartered in Silicon Valley, H7 BioCapital is a global venture platform that supports the transformational growth of healthcare companies through its influential venture capital financing, global accelerator program, venture club, VC class, webinars, conferences and other strategic events, and connect them with investors, scientists, physicians, corporate partners and other industrial professionals to jointly build a resource - rich healthcare innovation ecosystem. H7 BioCapital consists of three parts of organizations: H7 Accelerator, H7 Venture, and H7 Café to support the transformational growth of healthcare by striving to be transformational itself. Need a boost with your healthcare startup? Let H7 be your support - Health, Heal, Happiness, Hope, Humanity, Home and Holistic! H7 Accelerator 3-month-long cohort-based healthcare accelerator program providing mentorship, funding and other support to early-stage biotech, medtech and device startups along with a lifelong network for these leaders and innovators. H7 Venture Investment platform providing early stage funding support to healthcare startups that are believed to have a long-term growth potential. H7 Café A high-quality startup community that supports the growth of healthcare entrepreneurs by frequent events such as networking, educational workshop, private deal flow meetings and other programs to connect the corporate, scientists, investor and founder ecosystem.

With a passion for advancing healthcare and a keen focus on fostering innovation, FHCV is dedicated to supporting companies developing new and transformative medicines, as well as investing in other venture capital funds operating in the life sciences sector. FHCV invests in companies that are pushing the boundaries of medical research and development, with a particular emphasis on those developing novel therapies. FHCV seeks out opportunities where breakthrough technologies and transformative ideas have the potential to address significant unmet medical needs and revolutionize patient care. The organization also invests in venture capital funds specializing in life sciences and seeks to leverage their expertise and network to access a diverse range of investment opportunities. This approach allows FHCV to diversify its portfolio while also benefiting from the specialized knowledge and due diligence capabilities of these investment partners.

The mission of the group is to identify early-stage companies with disruptive technologies that solve unmet needs in biologic drug R&D and production, as well as challenges in the diagnostics market. Investment selection is completed thorough a rigorous review process, which starts with in-depth market work, followed by due diligence according to Danaher’s best-in-class standard work.

Labena Ventures empowers CEE startups to scale globally. We take high-potential startup ventures on a fast-paced learning journey to help them explore and access business opportunities. Through highly-customized programmes, mentoring dedicated experts, as well as access to our vast network of business partners and investors, we help startups from all stages and across various industries on their way to international success. Labena Ventures, program aimed at scouting the most promising innovative startups and emerging companies throughout the Biotech, Pharma and Health value chains.